Our Pipeline at a glance

We have a proud legacy of turning breakthrough science into medicines and vaccines that save and improve lives around the world. We are focused on discovering new solutions for today and the future. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.

This table provides an overview of our late-stage clinical development programs and is updated quarterly. Updated February 23, 2024.

Download Merck Pipeline PDF

Our pipeline at a glance

80+

Programs in

Phase 2

30+

Programs in

Phase 3

10+

Programs

Under Review

Therapeutic area

Phase

Modality

Molecule Name Therapeutic Area
Potential Indications Status (i.e., Phase 2, 3, Under Review)
Modality

MK-8527

HIV-1 infection
Therapeutic area: Antiviral

Mechanism of Action: MK-8527 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) of HIV-1.

Modality: Small molecule

MK-8527

Mechanism of Action: MK-8527 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) of HIV-1.

Antiviral
HIV-1 infection
Small molecule

MK-6194

Systematic lupus erythematosus
Therapeutic area: Immunology

Mechanism of Action: MK-6194 is an investigational IL-2 mutein.

MK-6194 was acquired as part of the acquisition of Pandion Therapeutics

Modality: Small molecule

MK-6194

Mechanism of Action: MK-6194 is an investigational IL-2 mutein.

MK-6194 was acquired as part of the acquisition of Pandion Therapeutics

Immunology
Systematic lupus erythematosus
Small molecule

patritumab deruxtecan (MK-1022)

Previously treated locally advanced or metastatic EGFR-mutated NSCLC
Under Review (US)

(HERTHENA-Lung01; NCT04619004)

Non-small cell lung cancer (EU)
Therapeutic area: Oncology

Mechanism of Action: Patritumab deruxtecan is an investigational antibody-drug conjugate that consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.

Patritumab deruxtecan is being developed in collaboration with Daiichi Sankyo.

Modality: Antibody-drug conjugate

patritumab deruxtecan (MK-1022)

Mechanism of Action: Patritumab deruxtecan is an investigational antibody-drug conjugate that consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.

Patritumab deruxtecan is being developed in collaboration with Daiichi Sankyo.

Oncology
Previously treated locally advanced or metastatic EGFR-mutated NSCLC

(HERTHENA-Lung01; NCT04619004)

Under review (US)
Non-small cell lung cancer (EU)
Antibody-drug conjugate

ifinatamab deruxtecan (MK-2400)

Small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.

Ifinatamab deruxtecan is being developed in collaboration with Daiichi Sankyo.

Modality: Antibody-drug conjugate

ifinatamab deruxtecan (MK-2400)

Mechanism of Action: Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.

Ifinatamab deruxtecan is being developed in collaboration with Daiichi Sankyo.

Oncology
Small cell lung cancer
Antibody-drug conjugate

tulisokibart
(MK-7240)

Ulcerative colitis
Therapeutic area: Immunology

Mechanism of Action: MK-7240 is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).

MK-7240 was acquired as part of the acquisition of Prometheus Biosciences, Inc.

Modality: Monoclonal antibody

tulisokibart

(MK-7240)

Mechanism of Action: MK-7240 is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).

MK-7240 was acquired as part of the acquisition of Prometheus Biosciences, Inc.

Immunology
Ulcerative colitis
Monoclonal antibody

bomedemstat
(MK-3543)

Myeloproliferative disorders
Therapeutic area: Oncology

Mechanism of Action: Bomedemstat is an investigational lysine-specific demethylase-1 (LSD1) inhibitor.

Bomedemstat was acquired as part of the acquisition of Imago BioSciences, Inc.

Modality: Small molecule

bomedemstat

(MK-3543)

Mechanism of Action: Bomedemstat is an investigational lysine-specific demethylase-1 (LSD1) inhibitor.

Bomedemstat was acquired as part of the acquisition of Imago BioSciences, Inc.

Oncology
Myeloproliferative disorders
Small molecule

pembrolizumab + hyaluronidase subcutaneous
(MK-3475A)

Non-small cell lung cancer
Cutaneous squamous cell carcinoma
Therapeutic area: Oncology

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody fixed-dose combination

pembrolizumab + hyaluronidase subcutaneous

(MK-3475A)

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Non-small cell lung cancer
Cutaneous squamous cell carcinoma
Monoclonal antibody fixed-dose combination

V181

Dengue fever virus
Therapeutic area: Vaccines

Description: V181 is an investigational quadrivalent dengue vaccine.

Modality: Vaccine

V181

Description: V181 is an investigational quadrivalent dengue vaccine.

Vaccines
Dengue fever virus
Vaccine

MK-5684

Prostate cancer

(OMAHA1; NCT06136624, OMAHA2a; NCT06136650)

Therapeutic area: Oncology

Mechanism of Action: MK-5684 is an investigational oral inhibitor of cytochrome P450 11A1.

MK-5684 is being developed in collaboration with Orion.

Modality: Small molecule

MK-5684

Mechanism of Action: MK-5684 is an investigational oral inhibitor of cytochrome P450 11A1.

MK-5684 is being developed in collaboration with Orion.

Oncology
Prostate cancer

(OMAHA1; NCT06136624, OMAHA2a; NCT06136650)

Small molecule

LENVIMA®
(MK-7902)

Endometrial cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Therapeutic area: Oncology

Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

LENVIMA is being developed in combination with KEYTRUDA.

LENVIMA is being developed in collaboration with Eisai.

Modality: Small molecule

LENVIMA®

(MK-7902)

Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

LENVIMA is being developed in combination with KEYTRUDA.

LENVIMA is being developed in collaboration with Eisai.

Oncology
Endometrial cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Small molecule

MK-2870

Endometrial cancer
Neoplasm malignant
Therapeutic area: Oncology

Mechanism of Action: MK-2870 is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.

MK-2870 is being developed as monotherapy and/or in combination with KEYTRUDA.

MK-2870 is being developed in collaboration with Sichuan Kelun-Biotech.

Modality: Antibody-drug conjugate

MK-2870

Mechanism of Action: MK-2870 is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.

MK-2870 is being developed as monotherapy and/or in combination with KEYTRUDA.

MK-2870 is being developed in collaboration with Sichuan Kelun-Biotech.

Oncology
Endometrial cancer
NSCLC
Neoplasm malignant
Antibody-drug conjugate

islatravir + lenacapavir
(MK-8591D)

HIV-1 infection
Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.

MK-8591D is on FDA partial clinical hold for higher doses than those used in current clinical trials.

Islatravir is being developed under an agreement with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.

Modality: Small molecule fixed-dose combination

islatravir + lenacapavir

(MK-8591D)

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.

MK-8591D is on FDA partial clinical hold for higher doses than those used in current clinical trials.

Islatravir is being developed under an agreement with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

vibostolimab + pembrolizumab
(MK-7684A)

Melanoma
Non-small cell lung cancer
Small cell lung cancer
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Hepatocellular cancer
Ovarian cancer
Prostate cancer
Therapeutic area: Oncology

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody fixed-dose combination

vibostolimab + pembrolizumab

(MK-7684A)

Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Melanoma
Non-small cell lung cancer
Small cell lung cancer
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Gastric cancer
Head and neck squamous cell cancer
Hepatocellular cancer
Ovarian cancer
Prostate cancer
Monoclonal antibody fixed-dose combination

MK-0616

Hypercholesterolemia
Therapeutic area: Cardiovascular

Mechanism of Action: MK-0616 is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).

MK-0616 is being developed under an agreement with UCB Pharmaceuticals.

Modality: Peptide

MK-0616

Mechanism of Action: MK-0616 is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).

MK-0616 is being developed under an agreement with UCB Pharmaceuticals.

Cardiovascular
Hypercholesterolemia
Peptide

sotatercept
(MK-7962)

Pulmonary arterial hypertension
Under Review (US, EU)

(STELLAR; NCT04576988)

Pulmonary arterial hypertension
Pulmonary hypertension due to left heart disease
Therapeutic area: Cardiovascular

Mechanism of Action: Sotatercept is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors.

Sotatercept was acquired as part of the acquisition of Acceleron.

Modality: Therapeutic protein

sotatercept

(MK-7962)

Mechanism of Action: Sotatercept is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors.

Sotatercept was acquired as part of the acquisition of Acceleron.

Cardiovascular
Pulmonary arterial hypertension

(STELLAR; NCT04576988)

Under review (US, EU)
Pulmonary arterial hypertension
Pulmonary hypertension due to left heart disease
Therapeutic protein

favezelimab + pembrolizumab
(MK-4280A)

Bladder cancer
Cutaneous squamous cell carcinoma
Endometrial cancer
Esophageal cancer
Melanoma
Renal cell carcinoma
Colorectal cancer
Hematological malignancies
Therapeutic area: Oncology

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Modality: Monoclonal antibody fixed-dose combination

favezelimab + pembrolizumab

(MK-4280A)

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Oncology
Bladder cancer
Cutaneous squamous cell carcinoma
Endometrial cancer
Esophageal cancer
Melanoma
Renal cell carcinoma
Colorectal cancer
Hematological malignancies
Monoclonal antibody fixed-dose combination

WELIREG™
(MK-6482)

Previously treated advanced renal cell carcinoma
Under Review (EU)
von Hippel-Lindau disease-associated RCC
Under Review (EU)
Renal cell carcinoma
Endometrial cancer
Esophageal cancer
Hepatocellular carcinoma
Prostate
Rare cancers
Therapeutic area: Oncology

Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.

WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.

WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.

Modality: Small molecule

WELIREG™

(MK-6482)

Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.

WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.

WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.

Oncology
Previously treated advanced renal cell carcinoma
Under review (EU)
von Hippel-Lindau disease-associated RCC
Under review (EU)
Renal cell carcinoma
Endometrial cancer
Esophageal cancer
Hepatocellular carcinoma
Prostate
Rare cancers
Small molecule

boserolimab
(MK-5890)

Neoplasm malignant
Therapeutic area: Oncology

Mechanism of Action: Boserolimab is an investigational monoclonal antibody that binds and activates CD27.

Boserolimab is being developed in combination with KEYTRUDA.

Boserolimab is being developed under an agreement with Chinook Therapeutics.

Modality: Monoclonal antibody

boserolimab

(MK-5890)

Mechanism of Action: Boserolimab is an investigational monoclonal antibody that binds and activates CD27.

Boserolimab is being developed in combination with KEYTRUDA.

Boserolimab is being developed under an agreement with Chinook Therapeutics.

Oncology
Neoplasm malignant
Monoclonal antibody

zilovertamab vedotin
(MK-2140)

Hematological malignancies
Therapeutic area: Oncology

Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.

Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.

Modality: Antibody-drug conjugate

zilovertamab vedotin

(MK-2140)

Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.

Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.

Oncology
Hematological malignancies
Antibody-drug conjugate

KEYTRUDA®
(MK-3475) **

Resectable stage II, IIIA or IIIB non-small cell lung cancer
Under Review (EU, JPN)

(KN-671; NCT03425643)

1L HER2 negative locally advanced unresectable or metastatic gastric cancer
Under Review (JPN)

(KN-859; NCT03675737)

1L locally advanced unresectable metastatic biliary tract cancer
Under Review (JPN)

KN-966; NCT04003636)

1L locally advanced or metastatic urothelial cancer
Under Review (JPN)

(KNA39; NCT04223856)

High-risk locally advanced cervical cancer
Under Review (EU)

(KN-A18;  NCT04221945)

Primary advanced or recurrent endometrial carcinoma
Under Review (US)

(KN-868; NCT03914612)

Cutaneous squamous cell carcinoma (EU)
Hepatocellular carcinoma (EU)
Mesothelioma
Ovarian cancer
Small cell lung cancer
Prostate cancer
Advanced solid tumors
Therapeutic area: Oncology

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

**Select KEYTRUDA clinical trials are shown.

Modality: Monoclonal antibody

KEYTRUDA®

(MK-3475) **

Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

**Select KEYTRUDA clinical trials are shown.

Oncology
Resectable stage II, IIIA or IIIB non-small cell lung cancer

(KN-671; NCT03425643)

Under review (EU, JPN)
1L HER2 negative locally advanced unresectable or metastatic gastric cancer

(KN-859; NCT03675737)

Under review (JPN)
1L locally advanced unresectable metastatic biliary tract cancer

KN-966; NCT04003636)

Under review (JPN)
1L locally advanced or metastatic urothelial cancer

(KNA39; NCT04223856)

Under review (JPN)
High-risk locally advanced cervical cancer

(KN-A18;  NCT04221945)

Under review (EU)
Primary advanced or recurrent endometrial carcinoma

(KN-868; NCT03914612)

Under review (US)
Cutaneous squamous cell carcinoma (EU)
Hepatocellular carcinoma (EU)
Mesothelioma
Ovarian cancer
Small cell lung cancer
Prostate cancer
Advanced solid tumors
Monoclonal antibody

efinopegdutide
(MK-6024)

Nonalcoholic Steatohepatitis
Therapeutic area: Endocrinology

Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.

Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.

Modality: Peptide

efinopegdutide

(MK-6024)

Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.

Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.

Endocrinology
Nonalcoholic Steatohepatitis
Peptide

MK-2060

Thrombosis
Therapeutic area: Cardiovascular

Mechanism of Action: MK-2060 is an investigational monoclonal antibody that inhibits the activation of Factor XI and activity of Factor XIA.

MK-2060 is being developed under an agreement with Adimab.

Modality: Monoclonal antibody

MK-2060

Mechanism of Action: MK-2060 is an investigational monoclonal antibody that inhibits the activation of Factor XI and activity of Factor XIA.

MK-2060 is being developed under an agreement with Adimab.

Cardiovascular
Thrombosis
Monoclonal antibody

quavonlimab + pembrolizumab
(MK-1308A)

Renal cell carcinoma
Colorectal cancer
Therapeutic area: Oncology

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Modality: Monoclonal antibody fixed-dose combination

quavonlimab + pembrolizumab

(MK-1308A)

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Oncology
Renal cell carcinoma
Colorectal cancer
Monoclonal antibody fixed-dose combination

MK-5475

Pulmonary arterial hypertension
Therapeutic area: Cardiovascular

Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).

Modality: Small molecule

MK-5475

Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).

Cardiovascular
Pulmonary arterial hypertension
Small molecule

LYNPARZA®
(MK-7339)

Non-small cell lung cancer
Small cell lung cancer
Advanced solid tumors
Therapeutic area: Oncology

Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.

LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.

LYNPARZA is being developed in collaboration with AstraZeneca.

Modality: Small molecule

LYNPARZA®

(MK-7339)

Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.

LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.

LYNPARZA is being developed in collaboration with AstraZeneca.

Oncology
Non-small cell lung cancer
Small cell lung cancer
Advanced solid tumors
Small molecule

islatravir + MK-8507
(MK-8591B)

HIV-1 infection
Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591B is on FDA clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Modality: Small molecule fixed-dose combination

islatravir + MK-8507

(MK-8591B)

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591B is on FDA clinical hold.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

V940

Melanoma

(INTerpath-001;  NCT05933577)

 

NSCLC

(INTerpath-002;  NCT06077760)

Therapeutic area: Oncology

Mechanism of Action: V940 is an investigational mRNA-based individualized neoantigen therapy targeting tumor associated antigens expressed by a patient’s cancer cells.

V940 is being developed in combination with KEYTRUDA.

V940 is being developed in collaboration with Moderna.

Modality: Vaccine

V940

Mechanism of Action: V940 is an investigational mRNA-based individualized neoantigen therapy targeting tumor associated antigens expressed by a patient’s cancer cells.

V940 is being developed in combination with KEYTRUDA.

V940 is being developed in collaboration with Moderna.

Oncology
Melanoma

(INTerpath-001;  NCT05933577)

 

NSCLC

(INTerpath-002;  NCT06077760)

Vaccine

V116

Therapeutic area: Vaccines

Description: V116 is an investigational 21 valent pneumococcal conjugate vaccine.

Modality: Vaccine

V116

Description: V116 is an investigational 21 valent pneumococcal conjugate vaccine.

Vaccines
Pneumococcal, adult
Under review (US)
Pneumococcal, adult (EU)
Vaccine

LAGEVRIO™
(MK-4482)

COVID-19
Therapeutic area: Antiviral

Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.

LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP. LAGEVRIO is available in the U.S. under Emergency Use Authorization.

Modality: Small molecule

LAGEVRIO™

(MK-4482)

Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.

LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP. LAGEVRIO is available in the U.S. under Emergency Use Authorization.

Antiviral
COVID-19
(US)
Small molecule

islatravir + doravirine
(MK-8591A)

Therapeutic area: Antiviral

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591A is on FDA partial clinical hold for higher doses than those used in current clinical trials.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Modality: Small molecule fixed-dose combination

islatravir + doravirine

(MK-8591A)

Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

MK-8591A is on FDA partial clinical hold for higher doses than those used in current clinical trials.

Islatravir is being developed under an agreement with the Yamasa Corporation.

Antiviral
HIV-1 infection
Small molecule fixed-dose combination

favezelimab
(MK-4280)

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules.

Favezelimab is being developed in combination with KEYTRUDA.

Modality: Monoclonal antibody

favezelimab

(MK-4280)

Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules.

Favezelimab is being developed in combination with KEYTRUDA.

Oncology
Non-small cell lung cancer
Monoclonal antibody

quavonlimab
(MK-1308)

Non-small cell lung cancer
Therapeutic area: Oncology

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.

Quavonlimab is being developed in combination with KEYTRUDA.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Modality: Monoclonal antibody

quavonlimab

(MK-1308)

Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.

Quavonlimab is being developed in combination with KEYTRUDA.

Quavonlimab is being developed under an agreement with Akeso, Inc.

Oncology
Non-small cell lung cancer
Monoclonal antibody

nemtabrutinib
(MK-1026)

Hematological malignancies
Therapeutic area: Oncology

Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.

Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.

Modality: Small molecule

nemtabrutinib

(MK-1026)

Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.

Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.

Oncology
Hematological malignancies
Small molecule

gefapixant
(MK-7264)

Cough
Under Review (US*)
Therapeutic area: Respiratory

Mechanism of Action: Gefapixant is an investigational P2X3 receptor antagonist.

*In December 2023, FDA issued a CRL for the NDA for gefapixant. Merck is reviewing the feedback to determine next steps.

Gefapixant was acquired as part of the acquisition of Afferent Pharmaceuticals.

Modality: Small molecule

gefapixant

(MK-7264)

Mechanism of Action: Gefapixant is an investigational P2X3 receptor antagonist.

*In December 2023, FDA issued a CRL for the NDA for gefapixant. Merck is reviewing the feedback to determine next steps.

Gefapixant was acquired as part of the acquisition of Afferent Pharmaceuticals.

Respiratory
Cough
Under review (US*)
Small molecule

clesrovimab
(MK-1654)

Respiratory syncytial virus
Therapeutic area: Respiratory

Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.

Modality: Monoclonal antibody

clesrovimab

(MK-1654)

Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.

Respiratory
Respiratory syncytial virus
Monoclonal antibody

MK-8189

Schizophrenia
Therapeutic area: Neuroscience

Mechanism of Action: MK-8189 is an investigational inhibitor of phosphodiesterase 10A (PDE10A).

MK-8189 is being developed under an agreement with Royalty Pharma. Phase 2b development costs are being co-funded.

Modality: Small molecule

MK-8189

Mechanism of Action: MK-8189 is an investigational inhibitor of phosphodiesterase 10A (PDE10A).

MK-8189 is being developed under an agreement with Royalty Pharma. Phase 2b development costs are being co-funded.

Neuroscience
Schizophrenia
Small molecule

What do the phases of clinical trials mean?





No Duty to Update

The information contained in this chart was current as of February 23, 2024. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the pipeline chart and investors should not rely upon the information as current or accurate after February 23, 2024..

The chart reflects the company research pipeline as of February 23, 2024.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.